Gut microbiota and its metabolites: Key factors of drug resistance in the treatment of advanced prostate cancer (Review).
Prostate cancer (PCa) is a leading cause of cancer‑related deaths among men, and its incidence is increasing worldwide. Current treatments include androgen deprivation therapy, surgery, radiotherapy, chemotherapy and immunotherapy, among others. Surgical treatment has a less effective therapeutic effect in patients with advanced PCa. However, drug‑based treatments often lead to the development of drug resistance, highlighting the need to adopt new treatment strategies. The present review summarizes the role of gut microbiota and its metabolites in the treatment resistance of advanced PCa, potential microbiome‑targeted therapies and future research directions, for developing novel therapeutic approaches to overcome drug resistance and improve prognosis.
Authors
Song Song, Cui Cui, Yang Yang, Xu Xu, Liu Liu, Zhang Zhang, Liu Liu, Tian Tian, Che Che, Sun Sun, Zhang Zhang
View on Pubmed